Tradestie Institutional Equity Comparison Engine

CRMD vs AURA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRMD Overall Edge

CRMD Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while AURA counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRMD trades at 29.5x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRMD sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRMD
CRMD 29.5x vs AURA N/M Fwd P/E
Growth & Margin Winner CRMD
Op Margin 41.0% vs 0.0% ยท YoY -47.7% vs +0.0%
Momentum & Technical Winner AURA
1Y -58.2% vs +29.3% ยท 52W Pos 1% vs 50%
Options & Structure Winner AURA
BREAKDOWN (22nd %ile IV) vs CONSOLIDATION (17th %ile IV)
CRMD NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.70
-2.59% 1D
Market Cap $370.6M
1M Return -36.38%
1Y Return -58.23%
Forward P/E 29.5x
Unified AI Score
55.5 / 100 HOLD
Tech 60.0 Fund 62.0 Flow 70.0 Mom 55.0
AURA NASDAQ
Aura Biosciences, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.15
-0.97% 1D
Market Cap $740.0M
1M Return +13.67%
1Y Return +29.29%
Forward P/E N/M
Unified AI Score
35.2 / 100 SELL
Tech 13.0 Fund 44.0 Flow 69.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRMD -58.23% AURA +29.29% Spread: +87.52 pp (AURA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRMD TTM Op. Margin: 41.0% AURA TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRMD vs AURA. Trailing 12-month operating profitability (CRMD 41.0% vs AURA 0.0%) and valuation multiples (CRMD 29.5x vs AURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRMD (6) vs AURA (4)
Institutional Metric CRMD AURA Criterion Row Winner
Market Capitalization Scale $370.6M $740.0M Larger Scale AURA
Trailing P/E Ratio Valuation 2.4x N/M Lower Multiple CRMD
Forward P/E Ratio Valuation 29.5x N/M Lower Multiple CRMD
Revenue Growth (YoY) Growth -47.7% +0.0% Higher Growth AURA
Operating Margin (TTM) Profitability 41.0% 0.0% Higher Margin CRMD
Net Profit Margin Profitability 15.5% 0.0% Higher Margin CRMD
Return on Equity (ROE) Capital Efficiency 15.3% -61.7% Higher ROE CRMD
52-Week Range Position Momentum 1% ($5โ€“$13) 50% ($5โ€“$10) Stronger Trend AURA
Beta / 30D Volatility Risk Regime 1.22ฮฒ ยท 103% Vol 0.91ฮฒ ยท 74% Vol Lower Realized Risk AURA
Unified Institutional Score Composite Signal 55.5 / 100 (HOLD) 35.2 / 100 (SELL) Higher Composite CRMD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRMD vs AURA Buy Guide
CRMD BREAKDOWN
110d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 22nd %ile
IV Regime Compressed (<25th %ile)
Live CRMD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AURA CONSOLIDATION
136d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live AURA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRMD nor AURA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.